医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Anika to Highlight Regenerative Medicine and Orthobiologics Portfolio at 2019 Asia Pacific Orthopaedic Association Sports Meeting

2019年04月04日 AM05:05
このエントリーをはてなブックマークに追加


 

BEDFORD, Mass.

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced plans to showcase its regenerative medicine and orthobiologics portfolio at the 2019 Asia Pacific Orthopaedic Association (APOA) Sports Meeting. The global meeting, being held in Kuala Lumpur, Malaysia on April 4 – 6, will feature an educational symposium and hands-on simulated demonstrations on HYALOFAST, an HA-based scaffold for cartilage repair and regeneration, which anchors Anika’s regenerative medicine portfolio. In addition, Anika will also highlight its viscosupplement portfolio, which includes CINGAL and MONOVISC, at its booth #G02. The annual APOA Sports Meeting, which focuses on sports injuries, features live cadaveric demonstrations, live surgeries, workshops, and Meet the Expert sessions by distinguished global thought-leaders.

“Orthopedic sports medicine and sports-related injuries are an important focus for us given our extensive portfolio of treatments to address the continuum of orthopedic care from managing joint pain related to everyday and sports-related wear and tear to repairing cartilage defects,” said Joseph Darling, President and Chief Executive Officer of Anika Therapeutics. “We’re looking forward to presenting new clinical evidence and technical tips on the use of HYALOFAST at the APOA Sports Meeting to demonstrate the ease of use and clinical benefits of the minimally-invasive, one-step cartilage regeneration procedure to orthopedic surgeons from around the world.”

“As part of my clinical research, I have been using HYALOFAST for over eight years to treat cartilage lesions,” said Prof. Mahmut Nedim Doral, MD, APOA President and Chairman of the Department of Orthopaedics and Traumatology at UFUK University. “Clinical results utilizing HYALOFAST to repair cartilage in the ankle have been very satisfying for both myself and the many patients I treated. I am excited to be sharing my surgical techniques and results during Anika’s symposium at the APOA Sports Meeting 2019 in Kuala Lumpur.”

Below are the Anika-sponsored activities being held at the 2019 APOA Sports Meeting:

SYMPOSIUM: HYALOFAST One-Step Procedure in Cartilage Repair: Path-Breaking, Interactive Symposium
Friday, April 5, 2019
12:15 – 12:45pm
Hilton Kuala Lumpur – Lecture Hall B
Moderator: Prof. Mahmut Nedim Doral, MD, APOA President and Chairman of the Department of Orthopaedics and Traumatology at UFUK University in Ankara, Turkey
Topics/Speakers:

  • HYALOFAST plus microfracture for cartilage repair in the knee: 3-year results and surgical tips & tricks
    Dr. Tho Kam San, orthopedic surgeon at Gleneagles Hospital in Singapore
  • HYALOFAST in the treatment of osteochondral lesion of the ankle: surgical technique and clinical results
    Prof. Mahmut Nedim Doral

Anika Exhibit Booth #G02

  • Featuring the HYALOFAST arthroscopic virtual simulator for demonstrations on surgical application

About HYALOFAST

HYALOFAST is a non-woven, single-step, off-the-shelf, biodegradable HA-based scaffold for hyaline-like cartilage regeneration to treat cartilage injuries and defects. HYALOFAST is commercially available in approximately 15 countries and has been used to successfully treat approximately 16,000 patients internationally, and with strong eight-year patient follow-up data. HYALOFAST is pending regulatory submission in the United States and its FastTRACK Phase III trial is currently enrolling patients across the U.S. and Europe.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic and regenerative medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika’s orthopedic medicine portfolio includes ORTHOVISC®MONOVISC®, and CINGAL®, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190403005714/en/

CONTACT

For Investor Inquiries:
Anika Therapeutics, Inc.
Sylvia
Cheung, 781-457-9000
Chief Financial Officer

For Media Inquiries:
W2O Group
Sonal Vasudev, 917-523-1418
sonal@w2ogroup.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 拓臻生物公布其非酒精性脂肪性肝炎(NASH)候选药物-具有肝脏选择性的法尼醇X受体(FXR)激动剂TERN-101-临床Ⅰ期试验安全性和药效学研究结果
  • Terns Pharmaceuticals Announces Safety and Pharmacodynamic Results of a Phase 1 Clinical Trial of TERN-101, a Liver-Selective FXR Agonist in Development for the Treatment of NASH
  • AVITA Medical Half-Year Financial Report for Fiscal 2020
  • 西联汇款启动抗击新型冠状病毒的全球援助项目
  • Jinsan Beverage of Korea Introduces Its 5 Healthy Smoothies for Spring